Drug Profile
Research programme: Alzheimer's disease therapy - Thuris/D-Pharm
Alternative Names: Alzheimer's disease therapy research programme - Thuris/D-PharmLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Thuris Corporation
- Class Ethylenediamines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 28 Jul 2004 This programme is still in active development - BIO 2004 Annual International Convention (BIO-2004)
- 03 Sep 2002 Preclinical trials in Alzheimer's disease in USA (unspecified route)